Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Case report

Basal cell adenocarcinoma of the nasopharyngeal minor salivary glands: a case report and review of the literature

Authors: Jia Jin, Xia-Yun He

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Basal cell adenocarcinomas (BCACs) arise from the minor salivary glands in the upper respiratory tract and are extremely rare. In this report, we present an unusual case of a 57-year-old male with BCAC that arose from the nasopharynx. To our knowledge, this is the first case report of nasopharyngeal BCAC.

Case presentation

In August 2010, a 57-year-old Chinese male presented with epistaxis and decreased hearing for 1 month. He was diagnosed with BCAC of the solid type that arose from the nasopharynx. The patient received radiotherapy alone and exhibited a complete response. A follow-up at 72 months did not detect any evidence of disease recurrence or metastasis. A comprehensive literature review revealed only 7 previously reported cases of BCAC in the upper respiratory tract. Surgery is the first choice to treat BCAC but may impair maxillofacial function. Radiotherapy is reserved for inoperable cases.

Conclusions

Radiotherapy can achieve good local control and preserve maxillofacial function; therefore, this treatment may be a suitable option for patients who are not good candidates for surgery.

Chen KT. Carcinoma arising in monomorphic adenoma of the salivary gland. Am J Otolaryngol. 1985;6(1):39–41. https://doi.org/10.1016/S0196-0709(85)80007-7.CrossRefPubMed

Seifert G, Brocheriou C, Cardesa A, Eveson JW. WHO International Histological Classification of Tumours. Tentative Histological Classification of Salivary Gland Tumours. Pathol Res Prac. 1990;186(5):555–81. https://doi.org/10.1016/S0344-0338(11)80220-7.CrossRef

Parashar P, Baron E, Papadimitriou JC, Ord RA, Nikitakis NG. Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103(1):77–84. https://doi.org/10.1016/j.tripleo.2005.12.021.CrossRefPubMed

Skalova A, Michal M, Simpson RH. Newly described salivary gland tumors. Mod Pathol. 2017;30(s1):S27–43. https://doi.org/10.1038/modpathol.2016.167.CrossRefPubMed

Jayakrishnan A, Elmalah I, Hussain K, Odell EW. Basal cell adenocarcinoma in minor salivary glands. Histopathology. 2003;42(6):610–4. https://doi.org/10.1046/j.1365-2559.2003.01651.x.CrossRefPubMed

Chen S, Yang S, Chen X. Basal cell adenocarcinoma of the buccal minor salivary gland with liver metastases. Ann Saudi Med. 2015;35(4):318–20. https://doi.org/10.5144/0256-4947.2015.318.CrossRefPubMedPubMedCentral

Chong VF, Ong CK. Nasopharyngeal carcinoma. Eur J Radiol. 2008;66(3):437–47. https://doi.org/10.1016/j.ejrad.2008.03.029.CrossRefPubMed

Fonseca I, Soares J. Basal cell adenocarcinoma of minor salivary and seromucous glands of the head and neck region. Semin Diagn Pathol. 1996;13(2):128–37.PubMed

Warrick PD, Irish JC, Mancer K, Dardick I, Pynn BR, Gullane P. Basal cell adenocarcinoma: a rare malignancy of the salivary glands. J Otolaryngol. 2000;29(2):102–9.PubMed

10.

Jingu K, Hasegawa A, Mizo JE, Bessho H, Morikawa T, Tsuji H, Tsujii H, Kamada T. Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary reportof six cases and review of the literature. Radiat Oncol. 2010;5:89. https://doi.org/10.1186/1748-717X-5-89.CrossRefPubMedPubMedCentral

11.

He XY, Liu TF, He SQ, Huan SL, Pan ZQ. Late course accelerated hyperfractionated radiotherapy of nasopharyngeal carcinoma (LCAF). Radiother Oncol. 2007;85(1):29–35. https://doi.org/10.1016/j.radonc.2007.08.005.CrossRefPubMed

12.

Baddour HM Jr, Fedewa SA, Chen AY. Five- and 10-Year Cause-Specific Survival Rates in Carcinoma of the Minor Salivary Gland. JAMA Otolaryngol Head Neck Surg. 2016;142(1):67–73. https://doi.org/10.1001/jamaoto.2015.2805.CrossRefPubMed

13.

Loochtan MJ, Shaar M, Pambuccian S, Borrowdale RW. Subglottic Basal Cell Adenocarcinoma. Ann Otol Rhinol Laryngol. 2016;125(2):169–72. https://doi.org/10.1177/0003489415603720.CrossRefPubMed

14.

Yamagata K, Oka K, Yoshida H, Yanagawa T, Onizawa K, Yusa H, Ishikawa A, Okada N. Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report. Pathol Res Pract. 2006;202(6):475–80. https://doi.org/10.1016/j.prp.2005.12.009.CrossRefPubMed

15.

Wilson TC, Robinson RA. Basal cell adenocarcinoma and Basal cell adenoma of the salivary glands: a clinicopathological review of seventy tumors with comparison of morphologic features and growth control indices. Head Neck Pathol. 2015;9(2):205–13. https://doi.org/10.1007/s12105-014-0562-4 Epub 2014 Aug 21.CrossRefPubMed

16.

Ward BK, Seethala RR, Barnes EL, Lai SY. Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature. Head Neck Oncol. 2009;1:41. https://doi.org/10.1186/1758-3284-1-41.CrossRefPubMedPubMedCentral

17.

Zhan KY, Lentsch EJ. Basal cell adenocarcinoma of the major salivary glands: A population-level study of 509 cases. Laryngoscope. 2016;126(5):1086–90. https://doi.org/10.1002/lary.25713.CrossRefPubMed

18.

Cuthbertson DW, Raol N, Hicks J, Green L, Parke R. Minor salivary gland basal cell adenocarcinoma: a systematic review and report of a new case. JAMA Otolaryngol Head Neck Surg. 2015;141(3):276–83. https://doi.org/10.1001/jamaoto.2014.3344.CrossRefPubMed

19.

Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;36(9476):2041–54. https://doi.org/10.1016/S0140-6736(05)66698-6.CrossRef

Title: Basal cell adenocarcinoma of the nasopharyngeal minor salivary glands: a case report and review of the literature
Authors: Jia Jin
Xia-Yun He
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4803-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study

Quality assurance target for community-based breast cancer screening in China: a model simulation

Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)

Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Keynote webinar | Spotlight on antibody–drug conjugates in cancer